IMVT
Income statement / Annual
Last year (2024), Immunovant, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Immunovant, Inc.'s net income was -$259.34 M.
See Immunovant, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$231,000.00 |
$1.32 M |
$1.23 M |
$998,000.00 |
$21,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$231,000.00 |
-$1.32 M |
-$1.23 M |
-$998,000.00 |
-$21,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$225.43 M
|
$160.26 M
|
$101.81 M
|
$68.60 M
|
$47.93 M
|
$25.73 M
|
$135.26 M
|
| General & Administrative
Expenses |
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$18.15 M
|
$2.69 M
|
$1.48 M
|
| Selling & Marketing
Expenses |
-$231,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.69 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$18.15 M
|
$448.00
|
$1.48 M
|
| Other Expenses |
$12.50 M |
-$253,000.00 |
-$781,000.00 |
$328,000.00 |
$412,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$282.71 M |
$208.28 M |
$156.03 M |
$108.12 M |
$66.08 M |
$448.00 |
$136.74 M |
| Cost And Expenses |
$282.71 M |
$208.28 M |
$156.03 M |
$108.12 M |
$66.08 M |
$448.00 |
$136.74 M |
| Interest Income |
-$24.95 M |
$7.58 M |
$0.00 |
$0.00 |
$625.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$12.48 M |
$655,000.00 |
$0.00 |
$625,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$231,000.00
|
$1.32 M
|
$1.23 M
|
$998,000.00
|
$21,000.00
|
$10,000.00
|
$136.74 M
|
| EBITDA |
-$269.98 M
|
-$198.28 M
|
-$156.03 M
|
-$107.72 M
|
-$65.65 M
|
-$450.00
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$23.94 M
|
-$12.48 M
|
-$655,000.00
|
$328,000.00
|
-$625,000.00
|
$2.00
|
$0.00
|
| Income Before Tax |
-$258.77 M |
-$210.95 M |
-$156.81 M |
-$107.79 M |
-$66.29 M |
-$448.00 |
-$136.74 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$567,000.00 |
$9,000.00 |
-$84,000.00 |
-$358,000.00 |
$97,000.00 |
$19,000.00 |
$0.00 |
| Net Income |
-$259.34 M |
-$210.96 M |
-$156.73 M |
-$107.43 M |
-$66.39 M |
-$448.00 |
-$136.74 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
0 |
-13.68 |
| EPS Diluted |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
0 |
-13.67 |
| Weighted Average Shares
Out |
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Weighted Average Shares
Out Diluted |
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Link |
|
|
|
|
|
|
|
